-
241
Summary of post-treatment disease course measures from MDMA-AT publications.
منشور في 2025الموضوعات: -
242
-
243
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
244
-
245
-
246
-
247
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
248
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
249
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: -
250
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
251
-
252
-
253
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
منشور في 2025الموضوعات: -
254
-
255
-
256
-
257
-
258
B2 decreases glycolytic intermediates in cells.
منشور في 2025"…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …"
-
259
-
260